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INTRODUCTION 
 An elevated arterial blood pressure is probably the most important 
public health problem in both developing and developed countries. It is 
common, mostly asymptomatic, readily detectable, usually easily treatable, 
and often leads to lethal complications if left untreated.1 
 The prevalence of hypertension in white suburban population 
according to the Framingham study is nearly one fifth of individuals have 
blood pressures > 160/95 mm Hg, while almost one half have pressures        
> 140/90 mm Hg. In females the prevalence is closely related to age, with a 
substantial increase occurring after the age of 50. This increase is presumably 
related to the hormonal changes of menopause. Thus, the ratio of 
hypertension frequency in women versus men increases from 0.6 to 0.7 at 
age of 30 to 1.1 to 1.2 at the age of 65. 1 
Cardiovascular diseases caused 2.3 million deaths in India in the year 
2005 and this is projected to double by the year 2020. Hypertension is directly 
responsible for 57% of all stroke deaths and 24% of all coronary artery 
disease deaths in India. In India, it has been found that hypertension 
prevalence is 24% among men and 17% among women in the year 2007.2 
 Hypertension is considered to be present when a person’s systolic 
blood pressure is consistently 140 mm Hg or greater, and / or their diastolic 
blood pressure is consistently  90 mm  Hg or greater. Recently, The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood pressure has defined blood pressure 120 / 80 
mm Hg to 139/89 mm Hg as Pre-hypertension. Pre-hypertension is not a 
disease category; rather, it is a designation chosen to identify individuals at 
high risk of developing hypertension.3  
  Untreated hypertension will lead to various complications. 
Complications due to hypertension are related either to sustained elevations 
of blood pressure, with consequent changes in the vasculature and heart, or 
to atherosclerosis that accompanies and is accelerated by long standing 
hypertension. Cardiac complications are the major causes of morbidity and 
mortality in hypertension and preventing them is a major goal of therapy. 
Cardiac complications of hypertension includes left ventricular hypertrophy, 
left ventricular dysfunction, congestive cardiac failure, ventricular arrhythmias, 
myocardial infarction and sudden death.4 The other complications of 
hypertension includes occurrence of stroke, especially intracerebral 
hemorrhage and ischemic cerebral infarction, hypertensive retinopathy, 
hypertensive nephropathy, aortic dissection and so on.  
 There are now many classes of potentially available anti-hypertensive 
drugs of which five (ACE inhibitors, diuretics, beta blockers, calcium channel 
blockers and angiotension receptor blockers(ARBs) are suitable for single 
drug therapy based on efficacy and tolerability. The first line of drug therapy of 
choice for the treatment of hypertension is ACE inhibitors. 5 
 The involvement of inflammation and its mediators in hypertension, 
cardiovascular pathophysiology and atherogenesis is increasingly 
recognized6. Plasma level of inflammatory molecules such as C-reactive 
protein (CRP); cytokines, such as tumour necrosis factor-  (TNF- ) and 
interleukin-6 (IL-6); chemokines, such as monocyte chemoattractant protein 
(MCP-1) and adhesion molecules, such as P-selectin7 and leucocyte adhesion 
molecules, intercellular adhesion molecules (ICAM-1), are increased in 
patients with essential hypertension  and increased CRP level8  has also been 
reported to be a predictor of future cardiovascular disease such as incidence 
of coronary artery disease, myocardial infarction and cerebrovascular 
accidents such as stroke.9 
 None of the standard anti-hypertensive drugs has been found to be 
effective in reducing the levels of C-reactive protein which is a better predictor 
of future cardiovascular and cerebrovascular complications.  
 Vitamin C, one of the water soluble vitamin, being a strong reducing 
agent, provides protection to various organs against oxidizing agents, and 
reduces oxidation of low density lipoproteins and prevents deposition of 
atheromatous plaques and incidence of stroke. It helps in maintenance of 
vascular integrity through prostacyclin, antiplatelet and vasodilatory effects. 
Vitamin C improves endothelial dependent vasodilatation by improving nitric 
oxide activity in hypertensive patients.10 
 Several animal studies11 and clinical trials suggest that Vitamin C 
reduces C-reactive protein levels12 in addition to the reduction of blood 
pressure13 and oxidized LDL cholesterol levels. Hence this open-label 
prospective, randomized, parallel group study is undertaken to find out the 
efficacy and tolerability of  vitamin C as an add on therapy to standard anti 
hypertensive regimen in the reduction of C-reactive protein and blood 
pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
REVIEW OF LITERATURE 
Hypertension, commonly referred to as "high blood pressure", is a 
medical condition in which the blood pressure is chronically elevated. 
Hypertension can be classified as either  
1. Primary Hypertension 
2. Secondary Hypertension 
 Primary hypertension indicates that no specific medical cause can be found 
to explain a patient's condition. Secondary hypertension indicates that the 
high blood pressure is a result of (i.e. secondary to) another condition, such 
as kidney disease or certain tumors (especially of the adrenal gland). 
Persistent hypertension is one of the risk factors for strokes, heart attacks, 
heart failure and arterial aneurysm, and is a leading cause of chronic renal 
failure. Even moderate elevation of arterial blood pressure leads to shortened 
life expectancy. At severely high pressures, mean arterial pressures 50% or 
more above average, a person can expect to live not more than a few years 
unless appropriately treated.14  
Salt sensitivity 
Sodium is the environmental factor that has received the greatest 
attention. It is to be noted that approximately 60% of the essential 
hypertension population is responsive to sodium intake. This is due to the fact 
that increasing amounts of salt in a person's bloodstream causes the body to 
draw more water, increasing the pressure on the blood vessel walls.15 
Role of renin 
Renin is a hormone secreted by the juxtaglomerular cells of the kidney 
and linked with aldosterone in a negative feedback loop. The range of renin 
activity observed in hypertensive subjects tends to be broader than in 
normotensive individuals. In consequence, some hypertensive patients have 
been defined as having low-renin and others as having essential 
hypertension.  
Low-renin hypertension is more common in African Americans than 
Caucasians and may explain why they tend to respond better to diuretic 
therapy than drugs that interfere with the renin-angiotensin system. 
High Renin levels predispose to hypertension: Increased renin --> 
Increased angiotensin II --> Increased vasoconstriction, thirst/ADH and 
aldosterone --> Increased sodium re-absorption in the kidneys (DCT and CD) 
--> Increased blood pressure.16 
Genetics 
Hypertension is one of the most common complex disorders, with 
genetic heritability averaging 30%. Data supporting this view emerge from 
animal studies as well as in population studies in humans. Most of these 
studies support the concept that the inheritance is probably multifactorial or 
that a number of different genetic defects each have an elevated blood 
pressure as one of their phenotypic expressions.17 
More than 50 genes have been examined in association studies with 
hypertension, and the number is constantly growing.18 
Etiology of secondary hypertension 
Only in a small minority of patients with elevated arterial pressure, can 
a specific cause be identified. These individuals will probably have an 
endocrine or renal defect that, if corrected, could bring blood pressure back to 
normal values. 
Renal hypertension  
Hypertension produced by diseases of the kidney. This includes 
diseases such as polycystic kidney disease or glomerulonephritis.16 
Hypertension can also be produced by diseases of the renal arteries 
supplying the kidney. This is known as renovascular hypertension; it is 
thought that decreased perfusion of renal tissue due to stenosis of a main or 
branch renal artery activates the renin-angiotensin system.  
Adrenal hypertension  
Hypertension is a feature of a variety of adrenal cortical abnormalities. 
In primary aldosteronism there is a clear relationship between the 
aldosterone-induced sodium retention and the hypertension.  
In patients with pheochromocytoma increased secretion of 
catecholamines such as epinephrine and norepinephrine by a tumor (most 
often located in the adrenal medulla) causes excessive stimulation of 
adrenergic receptors, which results in peripheral vasoconstriction and cardiac 
stimulation. This diagnosis is confirmed by demonstrating increased urinary 
excretion of epinephrine and norepinephrine and/or their metabolites 
(vanillylmandelic acid).  
Hypercalcemia, Coarctation of aorta are other secondary causes of  
hypertension.  
Pathophysiology 
Most of the secondary mechanisms associated with hypertension are 
generally fully understood, and are outlined at secondary hypertension. 
However, those associated with essential (primary) hypertension are far less 
understood. What is known is that cardiac output is raised early in the disease 
course, with total peripheral resistance (TPR) normal; over the time cardiac 
output drops to normal levels but TPR is increased. Three theories have been 
proposed to explain this: 
Theory 1 : 
Inability of the kidneys to excrete sodium, resulting in natriuretic 
factors such as Atrial Natriuretic Factor being secreted to promote salt 
excretion with the side-effect of raising total peripheral resistance.19  
Theory 2 : 
An overactive renin-angiotension system leads to 
vasoconstriction and retention of sodium and water. The increase in 
blood volume leads to hypertension.20  
Theory 3 :  
An overactive sympathetic nervous system, leading to increased 
stress responses.21  
It is also known that hypertension is highly heritable and polygenic (caused by 
more than one gene) and a few candidate genes have been postulated in the 
etiology of this condition.18,19,20  
Signs and symptoms :  
Hypertension is usually found incidentally - "case finding" - by 
healthcare professionals during a routine checkup. The only test for 
hypertension is a blood pressure measurement. Hypertension in isolation 
usually produces no symptoms although some people report headaches, 
fatigue, dizziness, blurred vision, facial flushing or tinnitus.20,21 Malignant 
hypertension (or accelerated hypertension) is distinct as a late phase in the 
condition, and may present with headaches, blurred vision and end-organ 
damage. 
It is recognized that stressful situations can increase the blood pressure. 
Hypertension is often confused with mental tension, stress and anxiety. 
While chronic anxiety is associated with poor outcomes in people with 
hypertension, it alone does not cause it. Accelerated hypertension is 
associated with somnolence, confusion, visual disturbances, nausea and 
vomiting (hypertensive encephalopathy).22 
Complications 
While elevated blood pressure alone is not an illness, it often requires 
treatment due to its short- and long-term effects on many organs. The risk is 
increased for:  
1. Cerebrovascular accident (CVAs or strokes)  
2. Myocardial infarction (heart attack)  
3. Left ventricular dysfunction 
4. Cardiac arrhythmias 
5. Hypertensive cardiomyopathy (heart failure due to chronically high 
blood pressure)  
6. Hypertensive retinopathy - damage to the retina  
7. Hypertensive nephropathy - chronic renal failure due to chronically 
high blood pressure 
Pregnancy 
Although few women of childbearing age have high blood pressure, up 
to 10% develop hypertension of pregnancy. While generally benign, it may 
herald three complications of pregnancy: pre-eclampsia, HELLP syndrome 
and eclampsia. Follow-up and control with medication is therefore often 
necessary. 
Hypertension in Children and Adolescents 
As with adults, blood pressure is a variable parameter in children. It 
varies between individuals and within individuals from day to day and at 
various times of the day. The epidemic of childhood obesity, the risk of 
developing left ventricular hypertrophy, and evidence of the early 
development of atherosclerosis in children would make the detection of and 
intervention in childhood hypertension important to reduce long-term health 
risks; however, supporting data are lacking. 
Most childhood hypertension, particularly in preadolescents, is 
secondary to an underlying disorder. Renal parenchymal disease is the most 
common (60 to 70%) cause of hypertension. Adolescents usually have 
primary or essential hypertension, making up 85 to 95 % of cases. 23 
 
GRADING OF HYPERTENSION :24 
Sl. No Category Systolic BP 
(mm  Hg) 
Diastolic BP 
(mm  Hg) 
1 Normal < 130 <85 
2 High normal 130 – 139 85 – 90 
3 Mild hypertension 140 – 159 90 -99 
4 Moderate hypertension 160 -179 100 -109 
5 Severe hypertension > 180 > 110 
 
 
ACE INHIBITORS :  
 ACE inhibitors decreases blood pressure by inhibiting the conversion of 
Angiotensin I to Angiotension II, which increases the sodium and water 
retention, Increases the aldosterone secretion thereby raises the blood 
pressure. 
Enalapril  
 Enalapril maleate, the second ACE inhibitor approved in the United 
States, is a prodrug hydrolyzed by esterases in the liver to produce the active 
decarboxylic acid, enalaprilat. Enalaprilat is a highly potent inhibitor of ACE. 
Although it also contains a “praline surrogate”, enalaprilat differs from 
Captopril in that it is an analogue of a tripeptide rather than of a dipeptide.  
 Pharmacokinetics : 
  Enalapril is absorbed rapidly when given orally and has an oral 
bioavailability of about 60% ( not reduced by food). Although peak 
concentrations of enalapril in plasma occur within an hour, enalaprilat 
concentrations peak only after 3 to 4 hours. Enalapril has a half-life of only 1.3 
hours, but enalaprilat, because of tight binding to ACE, has a plasma half-life 
of about 11 hours. Nearly all the drug is eliminated by kidneys as either intact 
enalapril or enalaprilat. 25 
 The oral dosage of enalapril ranges from 2.5 mg to 40 mg daily (Single 
or Divided doses), with 2.5 mg and 5 mg daily being appropriate for the 
initiation of therapy for heart failure and hypertension, respectively.  
VITAMIN C 
Vitamin C or L-ascorbate is an essential nutrient for higher primates, 
and a small number of other species. The presence of ascorbate is required 
for a range of essential metabolic reactions in all animals and  plants and is 
produced internally by almost all organisms, humans being one notable 
exception. It is widely known as the vitamin whose deficiency causes scurvy 
in humans. It is also widely used as a food additive. 
The pharmacophore of vitamin C is the ascorbate ion. In living 
organisms, ascorbate is an antioxidant, as it protects the body against 
oxidative stress26, and is a cofactor in several vital enzymatic reactions.  
 
Biological significance 
Vitamin C is purely the L-enantiomer of ascorbate; the opposite D-
enantiomer has no physiological significance. Both forms are mirror images of 
the same molecular structure. When L-ascorbate, which is a strong reducing 
agent, carries out its reducing function, it is converted to its oxidized form, L-
dehydroascorbate. L-dehydroascorbate can then be reduced back to the 
active L-ascorbate form in the body by enzymes and glutathione.  
L-ascorbate is a weak sugar acid structurally related to glucose which 
naturally occurs either attached to a hydrogen ion, forming ascorbic acid, or to 
a metal ion, forming a mineral ascorbate. 
Functions 
In humans, vitamin C is a highly effective antioxidant, acting to lessen 
oxidative stress, a substrate for ascorbate peroxidase, as well as an enzyme 
cofactor for the biosynthesis of many important biochemicals. Vitamin C acts 
as an electron donor for eight different enzymes. 
These enzymes participate in collagen hydroxylation.27 These reactions 
add hydroxyl groups to the amino acids proline or lysine in the collagen 
molecule (via prolyl hydroxylase and lysyl hydroxylase), thereby allowing the 
collagen molecule to assume its triple helix structure and making vitamin C 
essential to the development and maintenance of scar tissue, blood vessels, 
and cartilage.28  
These enzymes are necessary for synthesis of carnitine.29 Carnitine is 
essential for the transport of fatty acids into mitochondria for ATP generation.  
Deficiency 
Scurvy is an avitaminosis resulting from lack of vitamin C, as without 
this vitamin, the synthesised collagen is too unstable to meet its function. 
Scurvy leads to the formation of liver spots on the skin, spongy gums, and 
bleeding from all mucous membranes. 
 The spots are most abundant on the thighs and legs, and a person 
with the ailment looks pale, feels depressed, and is partially immobilized. In 
advanced scurvy there are open, suppurating wounds and loss of teeth and, 
eventually, death. The human body cannot store vitamin C, and so the body 
soon depletes itself if fresh supplies are not consumed through the digestive 
system. 
History of human understanding of Vitamin C 
James Lind, a British Royal Navy surgeon  in 1747, identified that a 
quality in fruit prevented the disease of scurvy in what was the first recorded 
controlled experiment. 
The need to include fresh plant food or raw animal flesh in the diet to 
prevent disease was known from ancient times. Native people living in 
marginal areas incorporated this into their medicinal lore. For example, spruce 
needles were used in temperate zones in infusions, or the leaves from 
species of drought-resistant trees in desert areas.  
In 1536, the French explorer Jacques Cartier, exploring the St. 
Lawrence River, used the local natives' knowledge to save his men who were 
dying of scurvy. He boiled the needles of the arbor vitae tree to make a tea 
that was later shown to contain 50 mg of vitamin C per 100 grams. 
Throughout history, the benefit of plant food to survive long sea 
voyages has been occasionally recommended by authorities. John Woodall, 
the first appointed surgeon to the British East India Company, recommended 
the preventive and curative use of lemon juice in his book "The Surgeon's 
Mate", in 1617. The Dutch writer, Johann Bachstrom, in 1734, gave the firm 
opinion that "scurvy is solely owing to a total abstinence from fresh vegetable 
food, and greens; which alone is the primary cause of the disease." 
While the earliest documented case of scurvy was described by 
Hippocrates around the year 400 BC, the first attempt to give scientific basis 
for the cause of this disease was by a ship's surgeon in the British Royal 
Navy, James Lind. Scurvy was common among those with poor access to 
fresh fruit and vegetables, such as remote, isolated sailors and soldiers.  
While at sea in May 1747, Lind provided some crew members with two 
oranges and one lemon per day, in addition to normal rations, while others 
continued on cider, vinegar, sulfuric acid or seawater, along with their normal 
rations. In the history of science this is considered to be the first occurrence of 
a controlled experiment comparing results on two populations of a factor 
applied to one group only with all other factors the same. The results 
conclusively showed that citrus fruits prevented the disease. Lind published 
his work in 1753 in his Treatise on the Scurvy. 
Lind's work was slow to be noticed, partly because he gave conflicting 
evidence within the book, and partly because the British admiralty saw care 
for the well-being of crews as a sign of weakness. In addition, fresh fruit was 
very expensive to keep on board, whereas boiling it down to juice allowed 
easy storage but destroyed the vitamin (especially if boiled in copper kettles). 
Ship captains assumed wrongly that Lind's suggestions didn't work because 
those juices failed to cure scurvy. 
It was 1795 before the British navy adopted lemons or lime as standard 
issue at sea. Limes were more popular as they could be found in British West 
Indian Colonies, unlike lemons which weren't found in British Dominions, and 
were therefore more expensive. This practice led to the American use of the 
nickname "limey" to refer to the British. Captain James Cook had previously 
demonstrated and proven the principle of the advantages of fresh and 
preserved foods, such as sauerkraut, by taking his crews to the Hawaiian 
Islands and beyond without losing any of his men to scurvy. For this otherwise 
unheard of feat, the British Admiralty awarded him a medal. 
The name "antiscorbutic" was used in the eighteenth and nineteenth 
centuries as general term for those foods known to prevent scurvy, even 
though there was no understanding of the reason for this. These foods 
included but were not limited to: lemons, limes, and oranges; sauerkraut, 
cabbage, malt, and portable soup. 
In 1907, Axel Holst and Theodor Frolich, two Norwegian physicians 
studying beriberi contracted aboard ship's crews in the Norwegian Fishing 
Fleet, wanted a small test mammal to substitute for the pigeons they used. 
They fed guinea pigs their test diet, which had earlier produced beriberi in 
their pigeons, and were surprised when scurvy resulted instead. Until that 
time scurvy had not been observed in any organism apart from humans, and 
had been considered an exclusively human disease. 
Discovery of Vitamin C 
In 1912, the Polish-American biochemist Casimir Funk, while 
researching deficiency diseases, developed the concept of vitamins to refer to 
the nutrients which are essential to health. Then, from 1928 to 1933, the 
Hungarian research team of Joseph L Svirbely and Albert Szent-Gyorgyi and, 
independently, the American Charles Glen King, first isolated vitamin C and 
showed it to be ascorbic acid. For this, Szent-Gyorgyi was awarded the 1937 
Nobel Prize in Medicine. 
Therapeutic uses 
Since its discovery vitamin C has been considered by some 
enthusiastic proponents a "universal panacea", although this led to suspicions 
by others of it being over-hyped. Other proponents of high dose vitamin C 
consider that if it is given "in the right form, with the proper technique, in 
frequent enough doses, in high enough doses, along with certain additional 
agents and for a long enough period of time, it can prevent and, in many 
cases, cure, a wide range of common and/or lethal diseases, notably the 
common cold, hypertension and heart disease, Some proponents issued 
controversial statements involving it being a cure for AIDS, bird flu, and 
SARS.30 
Probably the most controversial issue, the putative role of ascorbate in 
the management of AIDS, is still unresolved for more than 16 years after the 
landmark study published in the Proceedings of National Academy of 
Sciences (USA) showing that non toxic doses of ascorbate suppress HIV 
replication in vitro.31 Other studies expanded on those results, but still, no 
large scale trials have yet been conducted.32  
In an animal model of lead intoxication, vitamin C demonstrated 
"protective effects" on lead-induced nerve and muscle abnormalities.33 In 
smokers, blood lead levels declined by an average of 81% when 
supplemented with 1000 mg of vitamin C, while 200 mg were ineffective, 
suggesting that vitamin C supplements may be an "economical and 
convenient" approach to reduce lead levels in the blood.34 The Journal of the 
American Medical Association published a study which concluded, based on 
an analysis of blood lead levels in the subjects of the Third National Health 
and Nutrition Examination Survey, that the independent, inverse relationship 
between lead levels and vitamin C in the blood, if causal, would "have public 
health implications for control of lead toxicity". 
Vitamin C has limited popularity as a treatment for autism spectrum 
symptoms. A 1993 study of 18 children with Autism Spectrum Disorder (ASD) 
found some symptoms reduced after treatment with vitamin C, but these 
results have not been replicated. Small clinical trials have found that vitamin C 
might improve the sperm count, sperm motility, and sperm morphology in 
infertile men35, or improve immune function related to the prevention and 
treatment of age-associated diseases.36 However, to date, no large clinical 
trials have verified these findings. 
A preliminary study published in the Annals of Surgery found that the 
early administration of antioxidant supplementation using α-tocopherol and 
ascorbic acid reduces the incidence of organ failure and shortens ICU length 
of stay in this cohort of critically ill surgical patients.37 More research on this 
topic is pending. 
Dehydroascorbic acid, the main form of oxidized vitamin C in the body, 
was shown to reduce neurological deficits and mortality following stroke, due 
to its ability to cross the blood-brain barrier, while "the antioxidant ascorbic 
acid (AA) or vitamin C does not penetrate the blood-brain barrier".38 In the 
study published by the Proceedings of the National Academy of Sciences in 
2001, the authors concluded that such "a pharmacological strategy to 
increase cerebral levels of ascorbate in stroke has tremendous potential to 
represent the timely translation of basic research into a relevant therapy for 
thromboembolic stroke in humans". No such "relevant therapies" are available 
yet. 
In January 2007 the US Food and Drug Administration approved a 
Phase I toxicity trial to determine the safe dosage of intravenous vitamin C as 
a possible cancer treatment for "patients who have exhausted all other 
conventional treatment options." Additional studies over several years would 
be needed to demonstrate whether it is effective. In February 2007, an 
uncontrolled study of 39 terminal cancer patients showed that, on subjective 
questionnaires, patients reported an increase in health, quality of life, and 
daily function after administration of high-dose intravenous vitamin C.39 The 
authors concluded that "Although there is still controversy regarding 
anticancer effects of vitamin C, the use of vitamin C is considered to be a safe 
and effective therapy to improve the quality of life of terminal cancer patients". 
A team of University of California researchers demonstrated for the first 
time that vitamin C supplements can lower C-reactive protein (CRP)40 levels 
in the blood. C-reactive protein is a marker of inflammation and chronic 
disease risk in humans. Chronic inflammation accompanied by low levels of 
CRP has been found in smokers, type 2 diabetics, hypertension and obese 
and overweight individuals. Another study showed Vitamin C given at the 
dose of 500 mg/day significantly reduced the Blood pressure and oxidized 
LDL cholesterol levels in hypertensive patients.41 
Adverse effects 
While being harmless in most typical quantities, as with all substances 
to which the human body is exposed, vitamin C can still cause harm under 
certain conditions. 
Common side-effects 
Relatively large doses of vitamin C (>10000 mg/day) may cause 
indigestion, particularly when taken on an empty stomach. 
When taken in large doses, vitamin C causes diarrhea. In one trial, 
doses upto 6 grams of ascorbic acid were given to 29 infants, 93 children of 
preschool and school age, and 20 adults for more than 1400 days. With the 
higher doses, toxic manifestations were observed in five adults and four 
infants. The signs and symptoms in adults were nausea, vomiting, diarrhea, 
flushing of the face, headache, fatigue and disturbed sleep. The main toxic 
reactions in the infants were skin rashes.42 
During the first month of pregnancy, high doses of vitamin C may 
suppress the production of progesterone from the corpus luteum. 
Progesterone, necessary for the maintenance of a pregnancy, is produced by 
the corpus luteum for the first few weeks, until the placenta is developed 
enough to produce its own source. By blocking this function of the corpus 
luteum, high doses of vitamin C    (>6000 mg) is theorized to induce an early 
miscarriage. In a group of spontaneously aborting women at the end of the 
first trimester, the mean values of vitamin C were significantly higher in the 
aborting group. However, the authors point out that this relationship may not 
necessarily be a causal one.43 
Chance of overdose 
As discussed previously, vitamin C exhibits remarkably low toxicity. 
The LD50 (the dose that will kill 50% of a population) in rats is generally 
accepted to be 11,900 milligrams per kilogram when taken orally.44 The LD50 
in humans remains unknown, owing to medical ethics that preclude 
experiments which would put patients at risk of harm. However, as with all 
substances tested in this way, the LD50 is taken as a guide to its toxicity in 
humans and no data to contradict this has been found. 
C-REACTIVE PROTEIN 
C-reactive protein (CRP) is a plasma protein, an acute phase protein 
produced by the liver. It is a member of the pentraxin family of proteins 
Genetics and biochemistry 
The CRP gene is located on the first chromosome (1q21-q23). CRP is 
a 224 residue protein with a monomer molar mass of 25106 Da, and native 
cyclic pentamer mass of 125530 Da. 
 Function 
CRP is a member of the class of acute phase reactants as its levels 
rise dramatically during inflammatory processes occurring in the body. This 
increment is due to a rise in the plasma concentration of IL-6, which is 
produced in macrophages, endothelial cells and T-cells. CRP binds to 
phosphorylcholine on microbes. It is thought to assist in complement binding 
to foreign and damaged cells and enhances phagocytosis by macrophages, 
which express a receptor for CRP. It is also believed to play an important role 
in innate immunity, as an early defense system against infections. The 
desirable levels of C-reactive protein should be less than 1 mg/dl in normal 
individuals. 
Diagnostic use 
CRP is used mainly as a marker of inflammation. Measuring and 
charting C-reactive protein values can prove useful in determining disease 
progress or the effectiveness of treatments. Blood, usually collected in a 
serum-separating tube, is analyzed in a medical laboratory or at the point of 
testing. 
Various analytical methods are available for CRP determination, such as 
ELISA, immunoturbidimetry, rapid immunodiffusion and visual agglutination.  
C-REACTIVE PROTEIN AND HYPERTENSION  AND CARDIOVASCULAR 
RISKS: 
 Several studies showed that there is increased incidence of  
complications of hypertension in patients with elevated C-reactive protein 
levels.45 
Cardiovascular disease (CVD) is currently the leading cause of death 
and disability in the developed world, and will soon overtake infectious 
disease as the pre-eminent cause of death worldwide.46 Atherosclerosis is the 
most important contributor to this substantial disease burden. Whereas 
previously considered a bland process, our current understanding of 
atherosclerosis suggests that it is a dynamic and progressive disease arising 
from a combination of endothelial damage/dysfunction47, thrombosis and 
inflammation.48 
A substantial body of evidence has suggested that four modifiable risk 
factors such as smoking, diabetes, hypertension and hyperlipidaemia account 
for a significant proportion of CVD, and that reduction of these risk factors 
leads to improved morbidity and mortality. However, these traditional risk 
factors are not present in up to half of patients presenting with a clinical 
manifestation of CVD. Hence, there has been enormous interest in the 
identification of other measurable CVD risk factors in persons without overt 
disease. This would allow for the introduction of targeted pre-emptive 
preventive measures to prevent future cardiovascular events. Several novel 
candidate markers of potential use have been identified and include  C-
reactive protein (CRP), lipoprotein (a), homocysteine and fibrinogen. 
CRP has emerged as a strong, robust and independent risk factor for 
CVD that appears to have significant clinical utility. It is a circulating acute 
phase reactant named initially for its capacity to bind to the c-polysaccharide 
of Streptococcus pneumoniae, and is synthesized primarily by the liver in 
response to IL-6 and IL-1 . As a risk assessment tool, it has several good 
points — it is very stable, with very little difference in values between fresh or 
frozen plasma and has a long half-life of upto 20 h.49 It normally circulates at 
very low levels, but acute inflammatory processes induce marked hepatic 
synthesis of CRP, which can induce a 100-fold serum increase.50 Evidence 
also shows that patients with hypertension have increased levels of C-reactive 
protein levels since inflammatory process and endothelial dysfunction 
contributes to the development and severity of hypertension.51 
Evidence has shown that, even in apparently healthy subjects, there is 
good and consistent significant relationship (in all populations) between 
baseline CRP levels and risk of future cardiovascular events (stroke, 
peripheral vascular disease, sudden cardiac death and myocardial 
infarction).52 In those with existing CVD, it has been shown to predict future 
cardiovascular events including recurrent ischaemia, atrial fibrillation, death, 
stroke and percutaneous coronary intervention.53 Elevated CRP also appears 
to correlate with softer plaques that are more prone to rupture.54 
 It is likely that CRP is more than simply an inflammatory marker of 
increased CVD risk, as deposits of CRP have been demonstrated, on 
immunohistochemical staining, in the vascular wall of atherosclerotic plaques, 
where it is co-localized with the terminal complement complex and appears to 
be involved in foam cell formation.55  
Of note, the investigation of arterial stiffness has gathered pace in 
recent years with the development of readily available noninvasive 
assessment techniques. Previous studies have shown increased large artery 
stiffness to be an additional predictor of both atherosclerosis and 
cardiovascular risk.56 
Two complementary studies further supports the value of CRP as a 
surrogate marker for severity of hypertension and atherosclerosis. In the one 
study, researchers add to an increasing body of evidence58 demonstrating a 
significant relationship between CRP and stiffness of large arteries (as an 
early marker of severity of hypertension and atherosclerosis59). In this study, 
radial artery pulse wave activity was studied in 391 asymptomatic, apparently 
low-risk patients (mean age 50.9 years, only 10% smokers and 16% on 
hypertensive treatment) undergoing primary prevention screening. In the 
second much smaller study of 83 higher risk hypertensive patients. 
Another study have shown a correlation between CRP and 
atherosclerosis of the abdominal aorta and renal arterial tree. Taken together, 
these two papers lend further support to the hypothesis that inflammation 
within the arterial wall of large arteries (as manifested by increased levels of 
CRP) exerts its vascular effects by decreasing large artery elasticity and 
increasing its stiffness, both markers of severity of hypertension and 
developing atherosclerosis.60 
 It have been proved  that inflammation may be involved in the initiation 
development and severity  of hypertension, with the exertion of pro 
inflammatory actions through several mediators, including adhesion 
molecules, chemokines, growth factors, heat shock proteins, endothelin-1 and 
angiotensin. Indeed, even a persistent low-grade inflammatory state could 
result in a high but within the 'normal range' concentrations of inflammatory 
cytokines. Certainly, low-grade inflammation has been associated with other 
components of the metabolic syndrome, and endothelial damage/dysfunction. 
 By impairing the capacity of the endothelium to generate vasodilating 
factors, particularly nitric oxide (NO), elevated cytokines may cause 
endothelial dysfunction, chronic impaired vasodilatation and hypertension.61 
Inflammation is also intimately related to thrombogenesis, which is of 
relevance since the main complications of hypertension (stroke, myocardial 
infarction) are mainly thrombosis-related. The possibility that hypertension 
may be an inflammatory disease may have implications for novel therapeutic 
strategies to decrease the morbidity as well as mortality of hypertension, and 
treat hypertensive target organ damage. Certainly, prospective data are 
required to assess the effects of interventions and impact on prognosis. 
The process of atherogenesis starts in early childhood and 
hypertension is simply one associated risk factor. It is therefore possible that 
inflammatory parameters are abnormal in essential hypertension and may 
simply indicate sub-clinical or early vascular disease or atherosclerosis. Many 
recent studies have suggested a direct relationship between CRP and 
hypertension.62,63,64,65,66,67 
It is more likely that the inflammation remains one part of the complex 
pathophysiology linking hypertension to vascular disease. This would help our 
understanding and management of hypertension, which continues to be a 
major disease risk factor and burden on our healthcare resources.68,69  
 
 
 
 
ROLE OF VITAMIN C IN HYPERTENSION AND CARDIO VASCUALAR 
RISKS  
Heart Disease  
Vitamin C has multiple actions that can reduce the risk of heart 
disease. Two recent studies have found that 500 mg daily can significantly 
reduce blood pressure. In a study 38 people with mild to moderate 
hypertension, researchers of the Boston University School of Medicine, 
reported that 500 mg daily of vitamin C supplements reduced blood pressure 
by almost 10 percent in just one month.70  
A separate study, by British researchers., of the Glenfield Hospital, 
Leicester, England, found that 500 mg daily of vitamin C reduced blood 
pressure by an average of 6 mmHg in 40 elderly men and women after three 
months.70 Researchers have also discovered that vitamin C can improve 
"endothelial dysfunction," a risk factor for heart disease characterized by stiff 
blood vessel and reduced blood flow. Diets high in a combination of saturated 
fat and refined carbohydrates increase endothelial dysfunction. British 
researchers determined that 500 mg/day of vitamin C could improve blood 
vessel flexibility.71 
Stroke  
Several studies have found that vitamin C can reduce the risk of stroke 
- and limit brain damage from strokes. In a study of 2,100 Japanese men and 
women, researchers of the Osaka City University Medical School, noted that 
subjects with the highest blood levels of vitamin C at the beginning of the 
study, suggestive of long-term vitamin C consumption, had the lowest risk of 
stroke after age 40. People above the age of 64 with high vitamin C levels 
were 41 percent less likely to suffer a stroke compared with those who had 
the lowest vitamin C levels. 72 
A recent study found that the oxidized form of vitamin C - that is, the 
type formed after fighting free radicals - efficiently enters the brain and is 
particularly good at minimizing the brain damage. In an animal study, 
researchers at Columbia University, New York City, found that in high doses 
dehydroascorbic acid, which the body normally makes from vitamin C (and 
can be converted back to vitamin C), reduced stroke damage by upto 95% in 
laboratory mice. The researchers recommended that dehydroascorbic acid be 
used as a "drug" in stroke patients. 
VITAMIN C IN THE REDUCTION OF C-REACTIVE PROTEIN LEVELS AND 
BLOOD PRESSURE 
Researchers from the Boston University School of Medicine and 
Oregon State University studied 39 patients with mild to moderate 
hypertension. About half of the patients took daily doses of 500 mg of vitamin 
C, also known as ascorbic acid, while the other half took a placebo. After one 
month, the average blood pressure of patients who took vitamin C dropped 
significantly more than that of patients in the placebo group, or 9.1 percent 
compared to 2.7 percent, respectively.73 Vitamin C reduces the production of 
C-Reactive protein levels from liver, thereby decreasing the incidence of 
occurrence of future cardiovascular risks and cerebrovascular accidents 
which occurs due to hypertension. 
 Studies have also shown that vitamin C also improves Endothelial 
dysfunction which commonly occurs in hypertensive patients. Vitamin C also 
reduces arterial stiffness and improves the vascular flexibility thereby 
decreases the blood pressure. Vitamin C , by its anti oxidant property 
decreases the degradation of Nitric oxide, a potent vasodilator, which occurs 
during oxidative stressful conditions such as hypertension thereby decreases 
the blood pressure in hypertensive individuals. None of the previous studies 
have shown the combined effect of vitamin C in the reduction of C reactive 
protein levels and blood pressure. Hence, this study was undertaken to find 
out the efficacy and tolerability of vitamin C as an add-on therapy to standard 
anti hypertensive therapy in the reduction of C-reactive protein levels and 
blood pressure in patients with mild to moderate hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
OBJECTIVES 
 
Primary Objective : 
 
  To evaluate the efficacy of Vitamin C as an add-on therapy to 
the standard anti-hypertensive regimen in the reduction of blood pressure and          
C- reactive protein levels in mild to moderate hypertension. 
 
Secondary Objective : 
 
  To evaluate the tolerability of Vitamin C as an add-on therapy to 
the standard anti-hypertensive regimen in the management of mild to 
moderate hypertension 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
METHODOLOGY 
Methodology 
 The study was undertaken in mild to moderate hypertensive patients to 
find out the efficacy and tolerability of vitamin C as an add-on therapy to the 
standard anti-hypertensive regimen in the reduction of blood pressure and         
C-reactive protein levels. The study was conducted in Institute of 
Pharmacology, Madras Medical College, Chennai in collaboration with 
Department of Internal medicine, Government General Hospital, Chennai. 
 
STUDY DESIGN : 
 
 This study was an open-label, randomized, comparative , prospective, 
parallel group study. 
 
STUDY CENTRE : 
 Hypertension clinic, 
 Department of Internal Medicine,  
 Madras Medical College, 
 Government General Hospital, 
 Chennai. 
 
STUDY PERIOD : 
 The study was carried out from November 2005 to December 2006. 
 
 
STUDY DURATION : 
 6 months for each patient 
STUDY POPULATION : 
 Patients attending the Out patient department of Hypertension clinic, 
Department of Internal Medicine, Government General Hospital, Chennai 
 
SAMPLE SIZE : 
 120 patients   
(30 patients in each group) 
 
STUDY PROCEDURE : 
 Inclusion criteria : 
 Patients of either sex 
 Patients in the age group of 18 – 65 years  
 Patients with mild to moderate hypertension  
(Mild hypertension : systolic blood pressure 140 – 159 mm 
Hg and diastolic blood pressure 90 – 99 mm Hg, Moderate 
hypertension : systolic blood pressure 160 – 179 mm Hg and 
diastolic blood pressure 100- 109mm Hg) 
 Patients with C reactive protein levels more than  
      10  mg /dl 
 Patients with Body Mass Index (BMI) of 18 – 25 
 Patients willing to give written informed consent 
 
 
 Exclusion criteria : 
 
 Patients with history of septic arthritis, meningitis, 
pneumonia 
 Patients with history of pyelonephritis, tonsillitis, otitis 
media 
 Patients with upper respiratory tract infection 
 Patients with any other active infection 
 Patients with rheumatoid arthritis, acute pancreatitis 
 Patients with any history of surgery in the recent past 3 
months 
 Patients with history of malignancies  
 Patients with history of myocardial infarction 
 Patients with evidence of gastrointestinal tract, renal, 
endocrine, cardiovascular abnormalities and any other 
major systemic illness 
 Pregnant and lactating women 
 Patients who cannot comply with the protocol 
 Patients not willing to give written informed consent 
 
The study commenced after obtaining approval from the Institutional 
Ethical Committee.  
 
 
ENROLLMENT VISIT : 
Patients who attended the Out patient department of Hypertension 
Clinic, Department of Internal Medicine, Government General Hospital, 
Chennai were explained in detail about the study procedure, purpose and its 
benefits. 
They were explained about the following : 
The purpose of this study was to  
• Achieve better blood pressure reduction  
• Reduce complications 
• Improve the quality of life in hypertensive patients 
Written informed consent was obtained from patients willing to 
participate in the study, in the prescribed format in the regional language prior 
to the performance of the study procedures. If the patient is illiterate, left 
thumb impression was sought. This was done in the presence of impartial 
witness. Patients advised to come on next day at 8.00 A.M on empty stomach 
for screening procedure.  
SCREENING ( Visit 0 ):  
 Patients who gave written informed consent for participation in the 
study were screened by detailed medical history, blood pressure monitoring , 
estimation of C-reactive protein levels, physical and systemic examination, 
baseline demographic characteristics were recorded. Blood was drawn for 
determining the hematological and serum biochemical tests. 529 patients 
were screened.  
 
 
LABORATORY INVESTIGATIONS : 
 The following laboratory investigations were done at screening  
1. Complete Hemogram : 
a. Hemoglobin 
b. Total WBC count 
c. Neutrophil count 
d. Lymphocyte count 
e.  Red Blood Cell count. 
2. Blood  Biochemistry 
a. Blood sugar 
b. Blood urea 
c. Serum creatinine 
3. Liver Function Tests 
a. SGOT 
b. SGPT 
c. SAP 
d. Total bilirubin 
e. Total protein 
f. Albumin                    
4. Urine Analysis 
5. C-reactive protein levels estimation  
Sample collection for Serum C-reactive protein  level estimation and 
other hematological and biochemical parameters estimation 
 
The subjects were asked to come on an empty stomach to  the 
Outpatient Department of Hypertension Clinic, Government General Hospital 
at 8.00 A.M. on the sample collection day.  On arrival at the hospital the 
subject’s vital signs were recorded and ascertaining that condition of the 
subject was normal. The blood samples for determining serum  C-reactive 
protein levels and other biochemical and hematological parameters were 
collected into the blood collection tubes by venepunture. At each sampling 
10ml of blood was drawn.All the vital signs were monitored at the end of the 
sampling and only when both the patient and clinician are confident, the 
subjects were allowed to go from the out patient department of the 
Hypertension clinic where the study was conducted.  The serum C-reactive 
protein levels was estimated using Enzyme Linked Immuno Sorbent Assay 
(ELISA) and other hematological and biochemical parameters were 
estimated. 
RECRUITMENT AND GROUPING : 
 Among 529 patients screened, 120 patients who fulfilled the inclusion 
and exclusion criteria were recruited for the study. The recruited 120 patients 
were randomized into four groups each consisting of 30 patients. 
GROUPING : 
 GROUP I  : Enalapril 5 mg BD  
 GROUP II : Enalapril 5 mg BD + Vitamin C 100 mg
   OD 
 GROUP III : Enalapril 5 mg BD + Vitamin C 250 mg
   OD 
 GROUP IV : Enalapril 5 mg BD + Vitamin C 500 mg 
   OD 
 
STUDY VISITS : 
VISIT 1 ( Base line ) : 
 Out of 529 patients screened, 120 patients with systolic blood pressure 
in the range of 140 – 179 mm Hg and diastolic blood pressure in the range of       
90 – 109 mm Hg with C-reactive protein levels in the range of 10 – 12 mg/dl 
were recruited for the study. The following procedures were done at visit I. 
 Randomization :  
¾ Randomization into four groups 
o Each group consisting of 30 patients 
o Group I patients were given Enalapril 5 mg BD 
o Group II patients were given Enalapril 5 mg BD along 
with Vitamin C 100 mg OD 
o Group III patients were given Enalapril 5 mg BD along 
with Vitamin C 250 mg OD 
o  Group IV patients were given Enalapril 5 mg BD along 
with Vitamin C 500 mg OD 
o Patient were given medication for two weeks 
o Instructed to come fortnightly to collect the medication 
o Patients were instructed to bring the empty foils at the 
end of 2 weeks to check the patients compliance  
o Patients blood pressure was recorded 
o Detailed medical history and clinical examination was 
done 
o Blood samples were collected for the estimation of               
C-reactive protein levels and routine hematological and 
biochemical parameters. 
o Patients were advised to report to the investigator as 
soon as possible in case of occurrence of any adverse 
effects 
o Patients were instructed to report to the investigator in 
case of occurrence of any other illness and intake of 
other medications for the same. 
VISIT 2 ( At the End of 1st month) : 
o Patients compliance was checked. 
o Patients blood pressure was recorded. 
o Detailed medical history and clinical examination were 
done. 
o Blood samples were collected for the estimation of               
C-reactive protein levels and routine hematological and 
biochemical parameters. 
o Medications were issued to the patients for 2 weeks. 
o Instructed to come fortnightly to collect the medication. 
o Patients were advised to report to the investigator as 
soon as possible in case of occurrence of any adverse 
effects. 
o Patients were instructed to report to the investigator in 
case of occurrence of any other illness and intake of 
other medications for the same. 
 
 
VISIT 3 ( At the End of 3rd month) : 
o Patients blood pressure was recorded. 
o Detailed medical history and clinical examination were 
done. 
o Blood samples were collected for the estimation of              
C-reactive protein levels and routine hematological and 
biochemical parameters. 
o Study medications were issued to the patients for 2 
weeks. 
o Instructed to come fortnightly to collect the medication. 
o Patients were instructed to bring the empty foils at the 
end of 2 weeks to check the patients compliance.  
o Patients were advised to report to the investigator as 
soon as possible in case of occurrence of any adverse 
effects. 
o Patients were instructed to report to the investigator in 
case of occurrence of any other illness and intake of 
other medications for the same. 
 
VISIT 4 ( At the End of 6th  month) : 
o Patients blood pressure was recorded. 
o Detailed medical history and clinical examination were 
done. 
o Blood samples were collected for the estimation of              
C-reactive protein levels and routine hematological and 
biochemical parameters. 
o Instructed to come fortnightly to collect the medication for 
2 weeks. 
o Patients were instructed to bring the empty foils at the 
end of 2 weeks to check the patient’s compliance . 
o Patients were advised to report to the investigator as 
soon as possible in case of occurrence of any adverse 
effects. 
o Patients were instructed to report to the investigator in 
case of occurrence of any other illness and intake of 
other medications for the same. 
o Patients were instructed to attend the Out Patient 
department of Hypertension clinic to get the medications 
regularly.  
 
This study was undertaken to find out the efficacy and 
tolerability of vitamin C as an add-on therapy to the standard anti 
hypertensive therapy in the reduction of blood pressure and C-reactive 
protein levels in the patients with mild to moderate hypertension. 
 
 
 
  
 
 
 
 
 
 
 
 
RESULTS 
RESULTS : 
 Out of 529 patients screened, 120 patients who fulfilled the inclusion 
and exclusion criteria were recruited for the study. They were randomized into 
four groups, Group I, Group II, Group III and Group IV, each consisting of 30 
patients.  
 Group I received standard anti hypertensive treatment Enalapril 5 mg 
BD, Group II received Vitamin C 100 mg OD along with Enalapril 5 mg BD, 
Group III received Vitamin C 250 mg OD along with Enalapril 5 mg BD and 
Group IV received Vitamin C 500 mg OD along with Enalapril 5 mg BD for a 
period of six months for each patient.  
Parameters were assessed at the baseline, at the end of 1st month, at 
the end of 3rd month and at the end of 6th month of study. Only 110 patients 
(28 in Group I , 27 in Group II, 28 in Group III and 28 in Group IV) completed 
the study. 
 
STATISTICAL ANALYSIS : 
 
Statistical analysis was done using One way Anova for comparison 
between groups and  Bonferonni’s test for multiple comparison. Analysis of 
adverse events  was done using Chi – Square test. 
 
 
 
 
 
CLINICAL STUDY FLOWCHART 
 
Excluded (n=171) 
C Reactive protein levels < 10mg/dl (154), High 
Blood urea (7), High SGOT(10) 
Randomization 
Blood investigations(n=291) 
       Recruitment (n=120) 
Screening Visit  (529) 
(History, clinical and physical examination) 
Excluded (n= 238) 
Border line HT (102), Diabetes (65), Respiratory tract infection (19), 
myocardial infarction (22), Rheumatoid Arthirits (9) , Abnormal BMI  
(14), H/O surgery (5), Lymphoma (1),Breast Carcinoma(1) 
 
                      Enrollment visit (529)  
             (Informed consent obtained) 
Group I 
Enalapril 5 mg 
BD (n=30) 
Drop outs = 2 
Group II 
Enalapril 5 mg 
BD+ Vit C 100 
mg OD (n=30) 
Drop outs = 3 
 
Group III 
Enalapril 5 mg 
BD+ Vit C 250 
mg OD (n=30) 
Drop outs = 2 
 
Group IV 
Enalapril 5 mg 
BD+ Vit C 500 
mg OD (n=30) 
Drop outs = 3 
 
DROP OUTS : 
SL NO GROUPS NO OF DROP OUTS 
1 Group I 2 
2 Group II 3 
3 Group III 2 
4 Group IV 3 
 
 
Reasons for Drop Outs : 
  
1. In Group I, one patient didn’t turn up after one month of study and 
the remaining one patient not willing to continue the study after 2 
months. 
2. In Group II, two patients didn’t turn up after 1 month of study 
commencement and one patient was not willing to continue in the 
study after 2 months. 
3. In Group III, two patients lost to follow up for the study after one 
month period. 
4. In Group IV, two patients lost to follow up after one month  and one 
patient withdrew his willingness to participate in the study after one 
month. 
 
 
 
 
AGE DISTRIBUTION 
Table 1 : 
GROUPS N Mean Std. 
Deviation 
ANOVA 
F-test 
             GROUP I 28 44.96 7.613 
GROUP II 27 46.30 8.203 
GROUP III 28 47.50 7.550 
GROUP IV 27 46.04 7.881 
Total 110 46.20 7.758 
 
F=0.49 
P=0.69 
Not 
Significant 
 
Figure 1 : 
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Table 1 :   
shows  
 
 The number of patients in study groups I, II, III & IV 
 
 
 Mean age was evenly distributed among the groups 
 
 
 
There was no statistical significant difference   among the study groups. 
 
 
 
Figure 1 : shows the diagrammatic representation of the age distribution in 
study groups . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BODY MASS INDEX 
Table 2 : 
 
GROUPS N Mean Std. Deviation ANOVA 
F-test 
             GROUP I 28 21.057 1.8136 
GROUP II 27 20.841 1.8952 
GROUP III 28 20.457 1.9667 
GROUP IV 27 20.393 1.7444 
Total 110 20.688 1.8524 
F=0.80 
P=0.49 
Not 
significant 
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Table 2 :  shows the mean body mass index of patients in each study group. 
 
There was no statistical significant difference among groups regarding 
BMI. 
 
 
Figure 2 :    shows the diagrammatic representation of the BMI of patients in 
each group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEX DISTRIBUTION 
 
Table 3 : 
 
 
 
SEX 
MALE FEMALE 
 
 
 
 
  GROUPS 
n  % 
 
n  % 
 
 
 
CHI 
SQUARE 
TEST 
GROUP I 22 78.6% 6 21.4% 
 
GROUP II 20 74.1% 7 25.9% 
 
GROUP III 22 78.6% 6 21.4% 
 
GROUP IV 22 81.5% 5 18.5% 
χ2=0.44  
 
P = 0.91 (not 
significant) 
 
 
Figure 3 : 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
%
 o
f p
at
ie
nt
s
Enalapril Enalapril+Vitamin C100 Enalapril+Vitamin C250 Enalapril+Vitamin C500
SEX DISTRIBUTION
Male
Female
 
 
 
 
 
 
 
 
Table 3 : shows the sex distribution in the study groups. 
 
Statistical analysis was done with Chi square test. There was no statistical 
significant difference among groups regarding sex distribution. 
 
Figure 3 : shows the bar diagram of sex distribution among the groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMAPARISON OF REDUCTION OF SYSTOLIC BLOOD PRESSURE 
 
Table 4 : 
 
Groups 
GROUP I GROUP II GROUP III GROUP IV 
Parameter Mean SD Mean SD Mean SD Mean SD 
Test of  
significance
Bonferonni 
test  
Multiple 
comparison 
 
SBP_base 
Line 
159.36 6.18 155.93 7.41 157.36 7.40 158.74 6.40 
F=1.35 
P=0.26 
(NS) 
NS 
 
SBP_1st 
month 
153.86 5.44 149.78 6.36 148.07 6.77 141.04 7.09 
F=21.28 
P=0.04 
(S) 
4 Vs 1,2,3 
 
SBP_3rd 
month 
147.93 5.64 142.52 7.56 141.79 7.04 129.70 3.50 
F=46.28 
P=0.001 
(S) 
4 Vs 1,2,3 
 
SBP_6th 
month 
139.21 7.57 124.52 18.97 121.57 20.37 119.48 3.07 
F=9.20 
P=0.001 
(S) 
4 Vs 1,2,3 
  
Significance 
F=53.0 
P=0.001(S) 
F=38.9 
P=0.001(S)
F=31.1 
P=0.001(S)
F=270.8 
P=0.001(S) 
 
Figure 4 : 
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Table 4 : shows the Mean SYSTOIC BLOOD PRESSURE  in each group at 
baseline, at the end of 1st month, of 3rd month and 6th month. 
 
At the baseline  
                                     
                        There was no statistical significant difference  
     among groups at baseline. 
 
At the end of 1st month  
 
    
BONFERRONI T- test shows statistical significant 
difference  in Group IV when compared with Group I,II & 
III at end of 1st month  
 
At the end of 3rd month                                                            
 
                     
BONFERRONI T- test shows statistical significant 
difference in Group IV when compared with Group I,II & 
III 
 
At the end of 6th month 
 
BONFERRONI T- test shows statistical significant 
difference in Group IV when compared with Group I, II & 
III 
 
 
 
 
 
Figure 4 : shows the diagrammatic representation of the mean SYSTOLIC 
BLOOD PRESSURE in all the study groups at base line, at the end of 1st 
month,  3rd month and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERCENTAGE REDUCTION OF SYSTOLIC BLOOD PRESSURE AMONG 
GROUPS 
 
 
 
Table 5 : 
 
 
 1ST MONTH 3RD MONTH 6TH MONTH 
GROUP I 3.45% 7.17% 12.64% 
GROUP II 3.94% 8.60% 20.14% 
GROUP III 5.9% 8.89% 22.74% 
GROUP IV 11.15% 18.29% 24.73% 
 
 
 
Figure 5 : 
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Table 5 :  
 
Shows the percentage reduction of systolic blood pressure from 
baseline, at the end of 1st month, 3rd month and 6th month among the study 
groups 
 
 
Figure 5 : 
 
Shows the diagrammatic representation of the percentage reduction of 
systolic blood pressure from baseline, at the end of 1st month, 3rd month and 
6th month among the study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF REDUCTION OF DIASTOLIC BLOOD PRESSURE 
AMONG GROUPS 
Table 6 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  Mean SD Mean SD Mean SD Mean SD Significance 
Bonferonni 
test  
Multiple 
comparison 
DBP_base 
Line 90.71 3.90 90.22 3.20 91.07 3.15 90.89 3.86 
F=0.29 
P=0.83(NS) NS 
DBP_1st 
month 86.50 4.17 85.52 3.12 84.36 3.13 83.59 3.18 
F=3.17 
P=0.07(NS) NS 
DBP_3rd 
month 84.29 3.76 83.22 2.90 82.79 2.90 78.33 2.35 
F=19.5 
P=0.04(S) 4 Vs 1,2,3 
DBP_6th 
month 81.21 4.40 80.26 3.38 80.01 3.46 76.59 2.41 
F=11.3 
P=0.001(S) 4 Vs 1,2,3 
Significance F=27.1 
P=0.001(S) 
F=38.8 
P=0.001(S) 
F=52.4 
P=0.001(S) 
F=118.2 
P=0.001(S)   
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Table 6 : shows the Mean DIASTOLIC BLOOD PRESSURE  in each group 
at baseline, at the end of 3rd month and 6th month. 
 
At the baseline 
                                     
                         There was no statistical significant difference  
      among  groups at baseline. 
 
At the end of 1st month  
 
    
BONFERRONI T- test shows  no statistical significant 
difference  between Groups 
 
At the end of 3rd month                                                            
 
                     
BONFERRONI T- test shows statistical significant 
difference in Group IV when compared with Group I,II & 
III 
 
 
At the end of 6th month 
 
BONFERRONI T- test shows statistical significant 
difference in Group IV when compared with Group I, II & 
III 
 
 
 
 
 
Figure 6 : shows the diagrammatic representation of the mean DIASTOLIC 
BLOOD PRESSURE in all the study groups at base line, at the end of 1st 
month, at the end of 3rd month and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERCENTAGE REDUCTION OF DIASTOLIC BLOOD 
PRESSURE 
 
Table 7 : 
 
 
 1ST MONTH 3RD MONTH 6TH MONTH 
GROUP I 4.64% 7.08% 10.47% 
GROUP II 5.21% 7.76% 11.04% 
GROUP III 7.37% 9.09% 11.27% 
GROUP IV 8.03% 12.72% 15.73% 
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Table 7 : 
  Shows the percentage reduction of diastolic blood pressure from 
baseline, at the end of 1st month, 3rd month and 6th month among the study 
groups 
 
 
Figure 7 : 
 Shows the schematic representation of the percentage reduction of 
diastolic blood pressure from baseline, at the end of 1st month, 3rd month and 
6th month among the study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF REDUCTION OF C REACTIVE PROTEIN LEVELS 
BETWEEN GROUPS 
Table 8 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  Mean SD Mean SD Mean SD Mean SD Significance 
Bonferonni 
test  
Multiple 
comparison 
CRP_base 
Line 11.15 .38 11.22 .36 11.24 0.41 11.26 0.51 
F=0.33 
 
P=0.81(NS) 
NS 
CRP_1st 
month 11.12 .32 10.32 .42 6.77 1.29 5.69 1.26 
F=20.99 
 P=0.02(S) 
4 Vs 1,2,3 
 
CRP_3rd 
month 11.11 .40 9.47 .50 5.08 0.96 1.29 0.96 
F=93.81 
P=0.001(S) 
4 Vs 1,2,3 
 
CRP_6th 
month 11.09 .38 8.39 .50 2.72 0.57 0.04 0.08 
F=137.45 
P=0.001(S) 
4 Vs 1,2,3 
 
Significance F=3.06 
P=0.27(NS) 
F=19.58 
P=0.07(NS) 
F=46.92 
P=0.03(S) 
F=100.2 
P=0.001(S)   
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Table 8 : shows the  mean C REACTIVE PROTEIN LEVELS  in each group 
at baseline, at the end of 1st month,  3rd month and 6th month. 
 
At the baseline 
                                     
                         There was no statistical significant difference 
       among groups at baseline. 
 
At the end of 1st month  
 
BONFERRONI T- test shows statistical significant 
difference of in Group IV when compared with Group I, 
II & III 
 
                         
At the end of 3rd month                                                            
 
                     
BONFERRONI T- test shows statistical significant 
difference of in Group IV when compared with Group I, 
II & III 
 
 
At the end of 6th month 
 
BONFERRONI T- test shows statistical significant 
difference of in Group IV when compared with Group I, 
II & III 
 
 
 
 
Figure 8 : shows the diagrammatic representation of the mean C REACTIVE 
PROTEIN LEVELS in all the study groups at base line, at the end of 1st 
month, 3rd month and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERCENTAGE REDUCTION OF C REACTIVE PROTEIN 
LEVELS 
 
 
Table 9 : 
 
 
 1ST MONTH 3RD MONTH 6TH MONTH 
GROUP I 0.27% 0.36% 0.54% 
GROUP II 8.02% 15.6% 25.22% 
GROUP III 39.77% 54.8% 75.8% 
GROUP IV 49.47% 88.54% 99.64% 
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Table 9 : 
 Shows the percentage reduction of C reactive protein levels from 
baseline, at the end of 1st month, 3rd month and 6th month among the study 
groups 
 
 
Figure 9 :  
 Shows the schematic representation of  percentage reduction of C 
reactive protein levels from baseline, at the end of 1st month, 3rd month and 6th 
month among the study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF CHANGE OF HEMOGLOBIN CONCENTRATION 
AMONG GROUPS 
 
Table 10 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  
Mean SD Mean SD Mean SD Mean SD 
 
 
Significance 
Hb_base 
Line 
11.23 1.40 11.21 1.17 11.30 1.05 11.30 1.07 F=0.04 
P=0.99(NS) 
Hb_1st 
month 
11.18 1.32 11.23 1.24 11.32 1.00 11.43 1.21 F=0.23 
P=0.88(NS) 
Hb_3rd 
month 
11.06 1.15 11.15 1.16 11.39 0.95 11.24 1.00 F=0.46 
P=0.71(NS) 
Hb_6th 
month 
10.94 1.03 11.40 1.22 11.41 0.91 11.49 1.00 F=1.57 
P=0.20(NS) 
    
Significance 
F=0.30 
P=0.82 (NS) 
F=0.22 
P=0.82 (NS) 
F=0.08 
P=0.97 (NS) 
F=0.29 
P=0.82 (NS) 
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Table 10 shows the mean HEMOGLOBIN LEVELS  in each group at  
 
baseline, at the end of 1st month, 3rd month and 6th month. 
 
At the baseline 
                                    
                        There was no statistical significant difference   among 
                groups at baseline. 
 
At the end of 1st month  
 
                        There was no statistical significant difference   among 
                groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups 
at the end of 3rd  month  
 
At the end of 6th month 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
 
Figure 10 : shows the diagrammatic representation of the mean Hemoglobin 
concentration  in all the study groups at base line, at the end of 1st month,    
3rd  month and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF BLOOD SUGAR CHANGES BETWEEN THE  
STUDY GROUPS 
Table 11: 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  
Mean SD Mean SD Mean SD Mean SD 
 
 
Significance 
BS_base 
Line 
95.61 15.83 98.85 13.48 90.86 13.92 97.22 13.34 F=1.63 
P=0.19(NS) 
BS_1st 
month 
96.07 12.45 97.07 13.31 91.64 12.33 97.30 10.74 F=1.28 
P=0.28(NS) 
BS_3rd 
month 
93.86 9.71 97.59 9.49 92.36 11.33 96.96 8.86 F=1.75 
P=0.18(NS) 
BS_6th 
month 
96.61 9.20 98.93 9.20 94.64 11.39 95.93 9.74 F=0.89 
P=0.44(NS) 
   
Significance 
F=0.27 
P=0.85NS) 
F=0.17 
P=0.91NS) 
F=0.49 
P=0.69(NS) 
F=0.09 
P=0.96(NS) 
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Table 11 shows the mean BLOOD SUGAR LEVELS  in each group at  
 
baseline, at the end of 1st month, 3rd month and 6th month. 
 
At the baseline 
                                    
                        There was no statistical significant difference among 
      groups at baseline. 
 
At the end of 1st month  
 
    
                         There was no statistical significant difference among 
       groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups      
at the end of 3rd  month  
 
At the end of 6th month 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
 
 
Figure 11 shows the diagrammatic representation of the mean Blood Sugar 
levels in all the study groups at base line, at the end of 1st month, 3rd month 
and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF BLOOD UREA CONCENTRATION AMONG 
TREATMENT GROUPS 
Table 12 : 
 
Groups 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  
Mean SD Mean SD Mean SD Mean SD 
 
 
Significance 
Urea_base 
Line 
26.36 7.18 26.67 5.01 28.07 7.49 28.30 6.28 F=0.61 
P=0.61(NS) 
Urea_1st 
month 
26.64 6.81 27.07 4.85 27.50 5.69 27.81 5.19 F=0.22 
P=0.88(NS) 
Urea_3rd 
month 
26.89 6.54 28.15 4.93 27.93 5.35 28.63 4.84 F=0.49 
P=0.68(NS) 
Urea_6th 
month 
27.29 6.05 26.96 4.87 28.36 5.35 29.30 4.96 F=1.08 
P=0.36(NS) 
 
Significance 
F=0.09 
P=0.96 (NS) 
F=0.46 
P=0.71 (NS) 
F=0.09 
P=0.96 (NS) 
F=0.37  
P=0.77 (NS) 
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Table 12  shows the mena Blood Urea levels in each group at  
 
baseline, at the end of 1st month, 3rd month and 6th month. 
 
At the baseline 
                                    
                        There was no statistical significant difference among 
               groups at baseline. 
 
At the end of 1st month  
 
 
                      There was no statistical significant difference among  
              groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups 
at the end of 3rd  month  
 
At the end of 6th month 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
 
Figure 12 shows the diagrammatic representation of the mean Blood Urea 
levels in all the study groups at base line, at the end of 1st month, 3rd month 
and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARSION OF SERUM CREATININE LEVELS 
AMONG TREATMENT GROUPS 
Table 13 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
 
Parameters 
  Mean SD Mean SD Mean SD Mean SD 
 
Significance 
Cre_base 
Line 
0.80 0.13 0.83 0.15 0.84 0.14 0.83 0.15 F=0.43 
P=0.73(NS) 
Cre_1st 
month 
0.80 0.12 0.80 0.12 0.77 0.11 0.79 0.11 F=0.36 
P=0.78(NS) 
Cre_3rd 
month 
0.77 0.11 0.76 0.12 0.78 0.13 0.78 0.08 F=0.22 
P=0.88(NS) 
Cre_6th 
month 
0.81 0.11 0.79 0.11 0.76 0.11 0.78 0.10 F=0.93 
P=0.43(NS) 
 
Significance 
F=0.55 
P=0.65(NS) 
F=1.445 
P=0.23(NS) 
F=1.95 
P=0.13(NS) 
F=1.11 
P=0.35(NS) 
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Table 13 shows the mean Serum Creatinine  levels in each group at  
 
baseline, at the end of 1st month, 3rd month and 6th month. 
 
At the baseline 
                                    
                        There was no statistical significant difference among 
      groups at baseline. 
 
At the end of 1st month  
 
                        There was no statistical significant difference among 
      groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups 
at the end of 3rd  month  
 
At the end of 6th month 
 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
Figure 13 shows the diagrammatic representation of the mean Serum 
Creatinine  levels in all the study groups at base line, at the end of 1st month, 
3rd month and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF CHANGES OF SGOT LEVELS AMONG 
TREATMENT GROUPS 
 
Table 14 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
Parameters 
  
Mean SD Mean SD Mean SD Mean SD 
 
Significance 
SGOT_base 
Line 
19.82 2.98 20.52 2.83 20.11 2.88 19.89 2.22 F=0.35 
P=0.79(NS) 
SGOT_1st 
month 
20.46 2.73 20.74 3.53 20.25 3.31 20.11 3.31 F=0.19 
P=0.89(NS) 
sgot_3rd 
month 
20.50 3.50 20.33 2.91 20.54 2.06 20.30 2.85 F=0.05 
P=0.99(NS) 
SGOT_6th 
month 
19.89 3.34 20.85 3.44 19.61 2.99 20.00 2.96 F=0.77 
P=0.55(NS) 
Significance F=0.37 
P=0.78(NS) 
F=0.14 
P=0.92(NS) 
F=0.52 
P=0.67(NS) 
F=0.09 
P=0.96(NS) 
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Table 14 shows  the mean AST (SGOT)   levels in each group at baseline, at 
the end of 1st month, 3rd month and 6th month. 
 
At the baseline 
                          
                         There was no statistical significant difference among 
       groups at baseline. 
 
At the end of 1st month  
 
    
                         There was no statistical significant difference among 
       groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups 
at the end of 3rd  month  
 
At the end of 6th month 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
 
Figure 14 shows  the diagrammatic representation of the mean AST (SGOT)  
levels in all the study groups at base line, at the end of 1st month, at the end of 
3rd and 6th month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF CHANGES OF SGPT LEVELS AMONG THE 
TREATMENT GROUPS 
Table 15 : 
 
Group 
GROUP I GROUP II GROUP III GROUP IV 
 
Parameters 
  Mean SD Mean SD Mean SD Mean SD 
 
Significance 
SGPT_base 
Line 
20.46 2.77 20.48 2.10 20.07 2.83 20.37 2.75 F=0.14 
P=0.93(NS) 
SGPT_1st 
month 
21.25 3.92 19.96 3.02 20.32 2.72 20.37 2.99 F=0.81 
P=0.48(NS) 
SGPT_3rd 
month 
21.71 4.06 20.48 3.33 19.57 3.34 20.93 3.16 F=1.83 
P=0.15(NS) 
SGPT_6th 
month 
21.54 3.92 19.48 3.14 20.18 2.21 20.70 3.57 F=1.93 
P=0.12(NS) 
Significane F=0.62 
P=0.60(NS) 
F=0.72 
P=0.54(NS) 
F=0.38 
P=0.67NS) 
F=0.20 
P=0.89(NS) 
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Table 15 shows  the  mean ALT (SGPT)   levels in each group at  
 
baseline, at the end of 1st month, at the end of 3rd month and 6th month. 
 
At the baseline 
                                    
                        There was no statistical significant difference among 
      groups at baseline. 
 
At the end of 1st month : 
 
    
                        There was no statistical significant difference among 
      groups at the end of 1st month 
 
At the end of 3rd month                                                            
 
                     
There is no statistical significant difference among groups 
at the end of 3rd  month  
 
At the end of 6th month 
 
There is no statistical significant difference among groups 
at the end of 6th  month  
 
 
 
Figure 15 the diagrammatic representation of the mean ALT (SGPT)  levels in 
all the study groups at base line, at the end of 1st month, 3rd month and 6th 
month. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF ADVERSE EFFECTS AMONG THE GROUPS 
 
Table 16 : 
 
 
Sl 
No 
 
Side 
effects 
 
GROUP 
I 
 
GROUP 
II 
 
GROUP 
III 
 
GROUP 
IV 
 
Chi 
square 
Test 
χ2 
 
 
 
P 
value 
1 Nausea 1 1 1 2 0.70 0.87 
2 Vomiting 0 0 1 1 2.40 0.56 
3 Dyspepsia 0 0 0 1 3.10 0.38 
4 Diarrhoea 0 0 0 1 3.10 0.38 
5 Dizziness 2 1 1 2 0.71 0.87 
6 Headache 1 0 1 1 1.00 0.8 
7 Cough 2 2 2 1 0.43 0.93 
8 Fatigue 2 2 2 1 0.43 0.93 
9 Total 8 6 8 10 1.45 0.69 
 
 
Table 17 : 
 
ADVERSE 
EFFECTS 
SL NO GROUPS 
PRESENT ABSENT 
TOTAL CHI 
SQUARE 
TEST 
1 GROUP I 8 20 28 
2 GROUP II 6 21 27 
3 GROUP III 8 20 28 
4 GROUP IV 10 17 27 
 
χ2 = 1.45 
P = 0.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16 : 
  Shows the occurrence of various adverse effects among the 
treatment groups and their statistical significance. 
 
Table 17 : 
 Shows the Adverse effects among the study groups. Data was 
analyzed using Chi-Square test and found there was no statistical significance 
(P=0.69) among the groups in the occurrence of adverse effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 : 
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Figure 16 :  
 Shows the diagrammatic representation of occurrence of various 
adverse effects among the treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
DISCUSSION 
DISCUSSION 
Hypertension , one of the leading cause of morbidity and mortality in 
both developing and developed countries. Hypertension when untreated, 
leads to various cardiovascular risks such as increased incidence of 
atherosclerosis, coronary artery disease and cerebrovascular risks such as 
stroke. It has been found that increased levels of C reactive protein  have 
been associated with increased incidence of stroke and other cardiovascular 
risks. 
It has been found that increased levels of C reactive protein in 
hypertensive patients decreases the elasticity of large arteries and increase 
the arterial stiffness. Hypertension, being an oxidative stress, there will be 
degradation of nitric oxide which is a potent endogenous vasodilator. The 
subsequent reduction of nitric oxide levels in hypertensive patients results in 
increased responsiveness to vasoconstrictor amines such as catecholamines 
which increases the blood pressure.  
 None of the anti-hypertensive drugs reduces the C reactive protein 
levels, which not only increases the arterial stiffness but also increases the 
risk of cardiovascular complications such as coronary artery disease and 
increased incidence of cerebrovascular accidents such as stroke. 
 Studies suggest that Vitamin C, a potent anti-oxidant by scavenging 
free radicals, prevents the degradation of nitric oxide decreases the 
constrictor response of catecholamines and aids in the reduction of blood 
pressure. Vitamin C in addition reduces the levels of C reactive protein which 
found to decrease the elasticity of larger arteries and increasing arterial 
stiffness. Vitamin C by reducing C reactive protein levels helps in decreasing 
the blood pressure in hypertensive patients and prevents its complications. 
 Hence  the study was undertaken to find out the efficacy and tolerability 
of Vitamin C as add on therapy to standard anti-hypertensive therapy  in the 
reduction  of  blood  pressure and C reactive protein levels in hypertensive 
patients. 
 The study was conducted in the Outpatient Department of 
Hypertension Clinic, Department of Internal Medicine, Madras Medical 
College and Government General Hospital, Chennai. 
 Out of 529 patients screened, 120 patients who fulfilled the inclusion 
and exclusion criteria were recruited for the study. They were randomized into 
four groups, Group I, Group II, Group III and Group IV, each group consisting 
of 30 patients. Group I received Enalapril 5 mg BD, Group II received 
Enalapril 5 mg BD with Vitamin C 100 mg OD, Group III received Enalapril 5 
mg BD with Vitamin C 250 mg OD and Group D received Enalapril 5 mg BD 
with Vitamin C 500 mg OD for a period of 6 months. 
 Efficacy variables such as Systolic blood pressure, Diastolic blood 
pressure and C reactive protein levels were measured at the baseline, at the 
end of 1st month, at the end of 3rd month and at the end of 6th month of the 
study. Other hematological investigations such as complete hemogram, blood 
sugar, blood urea, serum creatinine, Liver function tests such as SGOT, 
SGPT, serum alkaline phosphatase, total bilirubin, total protein, albumin were 
done at the baseline, at the end of 1st month, at the end of 3rd month and 6th 
month of the study. 
 Regarding demographic characteristics, parameters such as age 
distribution, body mass index and sex distribution were taken into account and 
analyzed for any statistical significance. There is no statistical significane 
among the study groups in demographic characteristics. 
 In this study, Vitamin C at the dose of 100 mg and 250 mg when added 
with Enalapril produces significant decrease in systolic blood pressure at the 
end of 1st month , 3rd month and 6th month. 
 Vitamin C at the dose of 500 mg when added with Enalapril 5 mg BD 
causes statistical significant  reduction of systolic blood pressure of 11.15% at 
the end of 1st month, reduction of 18.29% at the end of 3rd month and 24.73% 
at the end of 6th month of the study. Enalapril 5 mg BD alone group produces 
reduction of systolic blood pressure of 3.45% at the end of  1st month, 7.17% 
at the end of 3rd month and 12.64% at the end of 6th month of the study. 
 One study comparing 500 mg/day of vitamin C supplement  1 month, 
showed a significant decrease in systolic BP of 9.9 mm Hg74. Another study 
showed that Vitamin C 500mg once daily produced fall of  blood pressure by 
9% after 4 weeks of study.75, 76,77,78  
In this study, Vitamin C at the dose of 500 mg when added with 
Enalapril 5 mg BD causes statistical significant  reduction of diastolic blood 
pressure of  12.72% at the end of 3rd month and 15.73% at the end of 6th 
month of the study. Enalapril 5 mg BD alone group produces reduction of 
diastolic blood pressure of  7.08% at the end of 3rd month and 10.07% at the 
end of 6th month of the study. 
In our study, it has been found even though Group III showed 
significant reduction of C reactive protein levels, only patients in Group IV  
(Vitamin C 500 mg) showed reduction of C reactive protein  to the desirable 
level (<1mg/dl).  
In our study, it has been found that Vitamin C at the dose of 500 mg 
once daily when given along with Enalapril 5mg BD causes reduction of C 
reactive protein levels to 49.47% at the end of 1st month, 88.54% at the end 
of 3rd month and 99.64% at the end of 6th month when compared to Enalapril 
5mg OD alone group in which the reduction of C reactive protein level was 
0.27% at the end of 1st month, 0.36% at the end of 3rd month and 0.54% at 
the end of 6th month of the study. One study showed that ingestion of Vitamin 
C 250 mg / day and 500 mg / day showed significant reduction of  C reactive 
protein levels  at the end of 2 months79. 
Hence, it has been found even though Vitamin C 100mg and 250 mg 
Group showed reduction of systolic and diastolic blood pressure, only patients 
in Group III (Vitamin C 500 mg ) showed reduction of C reactive protein to 
desirable levels. 
Other hematological and biochemical parameters were measured at 
the baseline, at the end of 1st month, at the end of 3rd month and the end of 6th 
month and found to have no statistical difference among the study groups. 
Mild adverse effects such as nausea, vomiting , dyspepsia, diarrhea, 
dizziness, headache, cough and fatigue occurred among study groups which 
does not show any statistical significant difference (P=0.69) among the groups 
and all the adverse effects subsided without any medications. 
Hence, Vitamin C at the dose of 500 mg / day produces significant 
reduction of systolic and diastolic blood pressure with reduction of C reactive 
protein levels to the desirable levels. 
  
 
 
 
 
 
 
 
 
 
CONCLUSION 
CONCLUSION : 
From our study, we conclude that 
• Vitamin C at the dose of 500 mg OD as an add on therapy to 
Enalapril 5mg BD causes significant reduction of both systolic 
and diastolic blood pressure. 
• Vitamin C 500mg also significantly decreases the C reactive 
protein  to desirable levels. 
• Vitamin C 500mg OD supplementation to the standard           
anti-hypertensive drugs may produce better reduction of blood 
pressure and  C reactive protein levels. 
• Vitamin C 500 mg may be recommended as an adjuvant to 
regular anti-hypertensive regimen to reduce cardiovascular and 
cerebrovascular risks associated with hypertension. 
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APPENDICES 
 
  Appendix 1 
ABBREVATIONS 
• AA   : Ascorbic acid 
• ACE   :  Angiotensin converting enzyme 
• ADH   : Anti diuretic hormone 
• ALT   : Aspartate aminotransferase 
• ARBs   : Angiotensin receptor blockers 
• ASD   : Autism spectrum disorder 
• AST   : Aspartate aminotransferase 
• BMI   : Body mass index 
• BS   : Blood sugar 
• CD   : Collecting duct 
• Cre   : Creatinine 
• CRP   :  C-reactive protein 
• CVAs   :  Cerebrovascular accidents 
• CVD   : Cardiovascular disease 
• DBP   : Diastolic blood pressure 
• DCT   : Distal convoluted tubule 
• dl   : Deciliter 
• ELISA   : Enzyme linked immunosorbent assay 
• Hb   : Hemoglobin 
• HDL   : High density lipoprotein 
• HT   : Hypertension 
• ICAM-1  : Intercellular adhesion molecule 
• IL-6   : Interleukin 6 
• JAMA   : The Journal of the American Medical 
    Association 
• Kg   : Kilogram 
• LDL   : Low density lipoprotein 
• MCP-1  : Monocyte chemoattractant protein 
• Mg   : Milligram 
• MI   : Myocardial infarction 
• Mm Hg  : Millimeter of mercury 
• MR   : Mineralocorticoid receptor 
• RA   : Rheumatoid arthritis 
• RTI   : Respiratory tract infection 
• SAP   : Serum alkaline phosphatase 
• SBP   : Systolic blood pressure 
• SGOT   : Serum glutamic oxaloacetic  
    transaminase 
• SGPT   : Serumglutamic pyruvic transaminase 
• TNF-α  :  Tumor necrosis factor α 
• TPR   : Total peripheral resistance 
• Vit   : Vitamin 
 
 
Appendix 2 
Case Record Form 
Efficacy and tolerability of Vitamin C as an add on therapy to the 
standard anti-hypertensive regimen in the reduction of blood 
pressure and C reactive protein levels in hypertensive patients 
Name   : 
Age   : 
Sex   : 
O.P. No  : 
Group   : 
Randomization  No : 
Address  : 
Examination 
 
     a. General Examination 
 
     Weight            Height           BMI 
 
                          Pallor           Jaundice       Odema        Others 
 
                          Nutritional status 
 
      b. CVS Examination  :         Pulse  BP  
 
      c. RS   Examination :          
 
      d. Abdomen  Examination       
 
      e. CNS  Examination : 
 
Investigations : 
 
SL.NO PARAMETERS BASELINE 1ST 
MONTH 
3RD 
MONTH 
6TH 
MONTH 
1 C reactive 
protein 
    
2 Blood sugar     
3 Blood urea     
4 Serum 
Creatinine 
    
5 Hemoglobin     
6 Total count     
7 Differential 
count 
    
8 SGOT     
9 SGPT     
10 SAP     
11 Total bilirubin     
12 Total protein     
13 Serum albumin     
 
 
Adverse Effects : 
 
 
 
 
 
Concomitant Medications : 
 
 
 
Others : 
 
Tamil consent form       Appendix 3 
MŒî x¥òjš got« 
MŒÉ‹ jiy¥ò 
“ïu¤j mG¤j nehahËfS¡fhd eilKiw kh¤âiuíl‹ it£Ä‹ á v‹D« kUªâ‹ âw‹, ghJfh¥ò¤j‹ik, ïu¤j 
mG¤j« k‰W«  
á-Çah¡o› òuj¤â‹ Fiwjš g‰¿a x® kU¤Jt MŒî” 
bga®       òw nehahË v©.           
KftÇ       MŒî nr®¡if v©.          
       taJ    
       ghÈd« (    ) M©    (    ) bg© 
eh‹        taJ          v‹Dila RaÃidîl‹ 
k‰W« KG Rjªâu¤Jl‹ ïªj kU¤Jt MŒÉš v‹id nr®¤J¡ bfhŸs r«kâ¡»nw‹. 
MŒÉ‹ jiy¥ò 
“ïu¤j mG¤j nehahËfS¡fhd eilKiw kh¤âiuíl‹ it£Ä‹ á v‹D« kUªâ‹ âw‹, ghJfh¥ò¤j‹ik, ïu¤j 
mG¤j« k‰W«  
á-Çah¡o› òuj¤â‹ Fiwjš g‰¿a x® kU¤Jt MŒî” 
vd¡F És¡f¥g£l Ñœ¡f©l Éõa§fS¡F eh‹ vdJ r«kj¤ij jU»nw‹. 
• ïªj MŒÉ‹ neh¡f«, kU¤Jt KiwfŸ, gÇnrhjid KiwfŸ, vd¡F âU¥âíW« tifÆš És¡f¥g£ld. 
• gÇnrhjid brŒtj‰fhf v‹ clÈÈUªJ ïu¤j« k‰W« áWÚ® vL¡f¥gl nt©oíŸsjhf 
m¿»nw‹. 
• eh‹ vL¤J tU»‹w k‰W« K‹ c£bfh©l kUªJfŸ g‰¿a Étu§fis MŒthsÇl« m¿É¡f 
r«kj«. ïªj g§nf‰wÈ‹ ã‹ò mtÇ‹ mDkâÆ‹¿ eh‹ vªj kUªJ« c£bfhŸs kh£nl‹ v‹W« 
bjÇÉ¡»nw‹. 
• vd¡F« k‰W« kUªJ MœthsU¡F«, ïªj MŒÉÈUªJ vªj xU ÃiyÆY« ÉyFtj‰nfh mšyJ 
Éy¡Ftj‰nfh KG cÇik ïU¥gjhf m¿»nw‹. 
• v‹Dila kU¤Jt¡ F¿¥ngLfis ïªj MŒÉš ga‹gL¤â¡ bfhŸs r«kâ¡»nw‹. MŒî ikaK«, 
MœthsU« v‹Dila bga® k‰W« áy Étu§fis ïufáakhf it¥gjhf m¿»nw‹. 
 
 
 
 
    
nehahËÆ‹ bga® 
     
ifbaG¤J 
   
njâ 
    
rh£áÆ‹ bga® 
     
ifbaG¤J 
   
njâ 
    
MŒthsÇ‹ bga® 
     
ifbaG¤J 
   
njâ 
 
 
 
 
Appendix 4 
PATIENT CONSENT FORM 
    “EFFICACY AND TOLERABILITY OF VITAMIN C AS AN ADD ON THERAPY TO THE 
STANDARD ANTI-HYPERTENSIVE REGIMEN IN THE REDUCTION OF BLOOD 
PRESSURE AND C REACTIVE PROTEIN LEVELS IN HYPERTENSIVE PATIENTS“ 
 
Study Centre  : Dept of Internal Medicine, Govt.General Hospital,Chennai. 
Patient’s Name  : ________________________________________ 
Patinet’s Age  : ________________________________________ 
Identification Number : ________________________________________ 
Patients may check (3  ) these Boxes  
I confirm that i have understood the purpose and procedure for the above study. I 
have the opportunity to ask the question and all my questions and doubts have 
been answered to my complete satisfaction. 
 
 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being 
affected. 
 
 
I understand that the investigator of the clinicl study, the ethics committee and 
the regulatory authorities will not need my permission to look at my health 
records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree to this 
access. However, I understand that my identify will not be revealed in any 
information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from this study.  
 
 
I agree to take part in the above study and to comply with the instructions given 
during the study and to faithfully co-operate with the study team, and to 
immediately inform the study staff if I suffer from any deterioration in my health or 
well being or any unexpected or unusual symptoms.  
 
 
I hereby agree to allow the investigator to take  blood from me for the laboratory 
investigations until the completion of study.. 
 
 
I hereby give permission to undergo complete physical examination, and 
diagnostic tests including hematological, Biochemical, Radiological and urine 
examination.   
 
 
Signature / Thumb Impression ______________________ Place  __________________ Date 
of the patient. 
Patient’s Name&Address : ___________________________________ 
__________________________________________________________ 
Signature of the Investigator : _____________________________ Place ______________ 
Date 
Study Investigator’s Name    : ____________________________________ 
